Articles and Publications
Explore our research and published work
Cardiovascular Diseases
Yaghoubi M, Javanbakht M, Mashayekhi A, Hemami MR, Branagan-Harris M, Keeble TR. Cost-effectiveness analysis of Intravascular Temperature Management after cardiac arrest in England – medRxiv, 2021
Javanbakht M, Mashayekhi A, Branagan-Harris M, Moloney E. Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England – PharmacoEconomics-Open, 2021
Javanbakht M, Mashayekhi A. PUK10 Cost–Utility Analysis of DyeVert Contrast Reduction Systems for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary and/or Peripheral Angiography – Value in Health, 2021
Bhattarai N, Price CI, McMeekin P, Javanbakht M, Vale L, Ford GA, et al. Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial – International Journal of Stroke, 2021
Price CI, Shaw L, Islam S, Javanbakht M, Watkins A, McMeekin P, et al. Effect of an enhanced Paramedic acute stroke treatment assessment on thrombolysis delivery during emergency stroke care: a cluster randomized clinical trial – JAMA neurology, 2020
Javanbakht M, Trevor M, Rezaei Hemami M, Rahimi K, Branagan-Harris M, Degener F, et al. Ticagrelor Removal by CytoSorb® in patients requiring emergent or urgent cardiac surgery: A UK-based cost-utility analysis – PharmacoEconomics-Open, 2020
Price C, Shaw L, Islam S, Javanbakht M, Watkins A, McMeekin P, et al. The challenge of mimic conditions during pre-hospital stroke research: screening data from the Paramedic Acute Stroke Treatment Assessment (PASTA) trial – International Journal of Stroke, 2019
Javanbakht M, Trevor M, Rahimi K, Branagan-Harris M, Degener F, Blanco DA, et al. COST UTILITY ANALYSIS OF TICAGRELOR REMOVAL BY CYTOSORB® IN PATIENTS REQUIRING EMERGENT OR URGENT CARDIAC SURGERY IN THE UK – ISPOR Europe, 2019
Javanbakht M, Trevor M, Rahimi K, Branagan-Harris M, Degener F, Blanco D, et al. PCV112 COST UTILITY ANALYSIS OF TICAGRELOR REMOVAL BY CYTOSORB® IN PATIENTS REQUIRING EMERGENT OR URGENT CARDIAC SURGERY IN THE UK – Value in Health, 2019
Endocrinology & Metabolic Diseases
Yaghoubi M, Mansell K, Vatanparast HH, Zeng W, Javanbakht M, Farag M. Patient level micro simulation model for evaluating the future potential cost effectiveness of pharmacy based interventions in the control and management of diabetes related complications in Canada – medRxiv, 2020
Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring versus self-monitoring of blood glucose in patients with type 1 diabetes in the UK – Diabetes Care, 2020
Gastroenterology
Javanbakht M, Mashayekhi A, Branagan-Harris M, Horvath P, Koenigsrainer A, Reymond MA, et al. Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis – European Journal of Surgical Oncology, 2021
E Moloney, A Mashayekhi, M Javanbakht, MR Hemami… Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal Surgery – PharmacoEconomics-Open, 2023
Javanbakht M, Mashayekhi A, Trevor M, Branagan-Harris M, Atkinson J. Cost-utility analysis of normothermic liver perfusion with the OrganOx metra compared to static cold storage in the United Kingdom – Journal of Medical Economics, 2020
Haematology
Moradi-Lakeh M, Yaghoubi M, Seitz P, Javanbakht M, Brock E. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland – Advances in Therapy, 2021
Infectious Diseases
Javanbakht M, Moradi-Lakeh M, Mashayekhi A, Atkinson J. Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility Analysis – PharmacoEconomics-Open, 2021
Muscoskeletal, Rheumatology, & Osteology
Mehdi Javanbakht, Atefeh Mashayekhi, Angeline Carlson, Eoin Moloney, Martyn Snow, James Murray, Tim Spalding Cost-Effectiveness Analysis of a Medial Meniscus Replacement Prosthesis for the Treatment of Patients with Medial Compartment Pain in the United Kingdom – PharmacoEconomics-Open, 2022
Nephrology, Renal, & Urology
Javanbakht M, Hemami MR, Mashayekhi A, Branagan-Harris M, Zaman A, Al-Najjar Y, et al. DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost–Utility Analysis – PharmacoEconomics-Open, 2020
Neurosciences
Ansaripour A, Roehrich K, Mashayekhi A, Wanjala M, Noel S, Hemami MR, et al. Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis – PharmacoEconomics-Open, 2021
Javanbakht M, Mashayekhi AM, Hemami MMR, Branagan-Harris M. High frequency chest wall oscillation system compared with manual chest wall physiotherapy for managing airway clearance in patients with complex neurological disorders: A UK-based cost-effectiveness analysis – European Respiratory Society, 2019
Javanbakht M, Mashayekhi A, Montazeri M, Rezai Hemami M, Branagan-Harris M. The vest™ high-frequency chest wall oscillation system compared with manual chest wall physiotherapy for managing airway clearance in patients with complex neurological disorders: a UK-based cost-effectiveness analysis – The Open Pharmacoeconomics & Health Economics Journal, 2019
NAFLD & NASH
M Javanbakht, J Fishman, E Moloney, P Rydqvist, A Ansaripour. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis – PharmacoEconomics-Open, 2023
Ansaripour A, & Fishman J, & Bowes K, Brown A, Nasserinejad K, Javanbakht M, Ahmadizar F. A systematic literature review, network meta-analysis, and cost-effectiveness analysis of resmetirom for the treatment of nonalcoholic steatohepatitis – Conference Paper, ISPOR 2023
A Ansaripour, J Fishman, E Moloney, M Javanbakht, EE227 The Impact of Treatment-Related Changes in Lipids on the Cost-Effectiveness of Resmetirom and Obeticholic Acid for Treatment of Nonalcoholic Steatohepatitis – Value in Health, 2023
M Javanbakht, J Fishman, E Moloney, P Rydqvist…Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis – PharmacoEconomics-Open, 2023
M Javanbakht, J Fishman, E Moloney, P Rydqvist, A Ansaripour EE313 Cost-Effectiveness Analysis of Resmetirom: An Investigational Treatment for the Management of Nonalcoholic Steatohepatitis – Value in Health, 2022
Oncology
E Moloney, A Mashayekhi, M Javanbakht, EE506 Targeted Intraoperative Radiation Therapy As an Adjuvant to Surgery for the Treatment of Breast Cancer in England: A UK-Based Cost-Effectiveness Analysis of Intrabeam – Value in Health, 2023
Other
Javanbakht M, Mashayekhi A, Trevor M, Rezaei Hemami M, L. Downey C, Branagan-Harris M, et al. Cost utility analysis of continuous and intermittent versus intermittent vital signs monitoring in patients admitted to surgical wards – Journal of Medical Economics, 2020
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study – The Lancet, 2017
Lozano R, Fullman N, Abate D, Abay SM, Abbafati C, Abbasi N, et al. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 – The Lancet, 2018
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 – The Lancet, 2018
Respiratory & Immuno-inflammatory
Javanbakht M, Saleh H, Hemami MR, Branagan-Harris M, Boiano M. A corticosteroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis: a UK-based cost-effectiveness analysis – PharmacoEconomics-Open, 2020.
Urinary Incontinence
Javanbakht M, Moloney E, Brazzelli M, Wallace S, Ternent L, Omar MI, et al. Economic evaluation of surgical treatments for women with stress urinary incontinence: a cost-utility and value of information analysis – BMJ Open, 2020
Javanbakht M, Moloney E, Brazzelli M, Wallace S, Omar MI, Monga A, et al. Surgical treatments for women with stress urinary incontinence: a systematic review of economic evidence – Systematic reviews, 2020
Javanbakht M, Mashayekhi A, Monga A, Atkinson J, Branagan-Harris M. Economic analysis of Electrical Muscle Stimulator with Multipath technology neuromuscular external electrical stimulation device for the treatment of stress urinary incontinence: a UK-based cost-utility analysis – JOURNAL OF MEDICAL ECONOMICS, 2020
Javanbakht M, Mashayekhi A, Monga A, Atkinson J, Branagan-Harris M. Economic analysis of Innovo® neuromuscular external electrical stimulation device for the treatment of stress urinary incontinence: A UK-based cost-utility analysis – Journal of Medical Economics, 2020
Javanbakht M, Mashayekhi A, Monga A, Atkinson J, Branagan-Harris M. Economic analysis of Electrical Muscle Stimulator with Multipath technology for the treatment of stress urinary incontinence: a UK-based cost-utility analysis – Journal of Medical Economics, 2020